Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes

Lusine Yaghjyan, Rulla M. Tamimi, Kimberly A. Bertrand, Christopher G. Scott, Matthew R. Jensen, V. Shane Pankratz, Kathleen R Brandt, Daniel W Visscher, Aaron Norman, Fergus J Couch, John Shepherd, Bo Fan, Yunn Yi Chen, Lin Ma, Andrew H. Beck, Steven R. Cummings, Karla Kerlikowske, Celine M Vachon

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Purpose: We examined the associations of mammographic breast density with breast cancer risk by tumor aggressiveness and by menopausal status and current postmenopausal hormone therapy. Methods: This study included 2596 invasive breast cancer cases and 4059 controls selected from participants of four nested case–control studies within four established cohorts: the Mayo Mammography Health Study, the Nurses’ Health Study, Nurses’ Health Study II, and San Francisco Mammography Registry. Percent breast density (PD), absolute dense (DA), and non-dense areas (NDA) were assessed from digitized film-screen mammograms using a computer-assisted threshold technique and standardized across studies. We used polytomous logistic regression to quantify the associations of breast density with breast cancer risk by tumor aggressiveness (defined as presence of at least two of the following tumor characteristics: size ≥2 cm, grade 2/3, ER-negative status, or positive nodes), stratified by menopausal status and current hormone therapy. Results: Overall, the positive association of PD and borderline inverse association of NDA with breast cancer risk was stronger in aggressive vs. non-aggressive tumors (≥51 vs. 11–25% OR 2.50, 95% CI 1.94–3.22 vs. OR 2.03, 95% CI 1.70–2.43, p-heterogeneity = 0.03; NDA 4th vs. 2nd quartile OR 0.54, 95% CI 0.41–0.70 vs. OR 0.71, 95% CI 0.59–0.85, p-heterogeneity = 0.07). However, there were no differences in the association of DA with breast cancer by aggressive status. In the stratified analysis, there was also evidence of a stronger association of PD and NDA with aggressive tumors among postmenopausal women and, in particular, current estrogen+progesterone users (≥51 vs. 11–25% OR 3.24, 95% CI 1.75–6.00 vs. OR 1.93, 95% CI 1.25–2.98, p-heterogeneity = 0.01; NDA 4th vs. 2nd quartile OR 0.43, 95% CI 0.21–0.85 vs. OR 0.56, 95% CI 0.35–0.89, p-heterogeneity = 0.01), even though the interaction was not significant. Conclusion: Our findings suggest that associations of mammographic density with breast cancer risk differ by tumor aggressiveness. While there was no strong evidence that these associations differed by menopausal status or hormone therapy, they did appear more prominent among current estrogen+progesterone users.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalBreast Cancer Research and Treatment
DOIs
StateAccepted/In press - Jun 17 2017

    Fingerprint

Keywords

  • Breast cancer subtypes
  • Breast density
  • Postmenopausal hormone therapy
  • Tumor aggressiveness

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yaghjyan, L., Tamimi, R. M., Bertrand, K. A., Scott, C. G., Jensen, M. R., Pankratz, V. S., Brandt, K. R., Visscher, D. W., Norman, A., Couch, F. J., Shepherd, J., Fan, B., Chen, Y. Y., Ma, L., Beck, A. H., Cummings, S. R., Kerlikowske, K., & Vachon, C. M. (Accepted/In press). Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes. Breast Cancer Research and Treatment, 1-11. https://doi.org/10.1007/s10549-017-4341-2